Telomerase: is it the future diagnostic and prognostic tool in human cancer?

References

• Moyzis RK, Buckingham JM, Cram LS et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc. Natl Acad. Sci. USA 85, 6622–6626 (1988).
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Structure and function of telomeres. Nature 350, 569–573 (1991).
   PubMed Web of Science ®Google Scholar
• Greider CW. Telomeres. Curr. Opin. Cell Biol. 3, 444–451 (1991).
   PubMed Web of Science ®Google Scholar
• Hastie ND, Dempster M, Dunlop MG. Telomere reduction in human colorectal carcinoma with ageing. Nature 346, 866–868 (1990).
   PubMed Web of Science ®Google Scholar
• Lindsey J, McGill NI, Lidsey LA et al. In vivo loss of telomeric repets with age in humans. Mut. Res. 256, 45–48 (1991).
   PubMed Web of Science ®Google Scholar
• Harley CB, Futcher AB, Greider CW. Telomerase shorten during ageing of human fibroblasts. Nature 345, 458–460 (1991).
   PubMedGoogle Scholar
• Levy MZ, Allsop RC, Futcher AB et al. Telomere end-replication problem and cell aging. J. Mol. Biol. 225, 951–960 (1992).
   PubMed Web of Science ®Google Scholar
• Allsopp RC, Chang E, Kashefi-Aazam M et al. Telomere shortening is associated with cell division in vitro and in vivo. Exp. Cell Res. 220, 194–200 (1995).
   PubMedGoogle Scholar
• Kang MK, Park NH. Conversion of normal to malignant phenotype: telomere shortening, telomerase activation, and genomic instability during immortalisation of human oral keratinocytes. Crit. Rev. Oral Biol. Med. 12, 38–54 (2001).
   PubMedGoogle Scholar
• Morin GB. The human telomere terminal transferase enzyme is ribonucleoprotein that synthesises TTAGG repeats. Cell 59, 521–529 (1989).
   PubMed Web of Science ®Google Scholar
• Greider CW, Blackburn EH. Identification of specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43, 405–413 (1985).
   PubMed Web of Science ®Google Scholar
• Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leades to elongation of telomerase and extended replicative lifespan. Curr. Biol. 8, 279–282 (1998).
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszek MA, Prowse et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 22011–2015 (1994).
   Google Scholar
• Feng J, Funk WD, Wang SS et al. The RNA component of human telomerase. Science 269, 1236–1241 (1995).
   PubMed Web of Science ®Google Scholar
• Meyerson M, Counter CM, Eaton EN et al. hEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumour cells and during iommortalization. Cell 90, 785–795 (1997).
   PubMed Web of Science ®Google Scholar
• Nakumura TM, Morin GB, Chapman KB et al. Telomerase catalytic subunit homolgus from fussion yeast and human. Science 277, 995–959 (1997).
   Google Scholar
• Krupp G, Bonatz G, Parwaresch R. Telomerase, immortality and cancer. Biotech. Ann. Rev. 6, 103–140 (2000).
   PubMedGoogle Scholar
• Kilian A, Bowtell DD, Abud HE et al. Isolation of candidate human telomerase catalytic subunit gene, which reveal complex splicing patterns in different cell types. Hum. Mol. Genet. 6, 2011–2019 (1997).
   PubMed Web of Science ®Google Scholar
• Ulaner GA, Hu JF, Vu TH. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternative splicing of hTERT transcripts. Cancer Res. 58, 4168–4172 (1998).
   PubMed Web of Science ®Google Scholar
• Dez C, Henras B, Faucon D et al. Stable expression in yeast of the mature form of human telomerase RNA depends on its association with the boxH/ACA small nuclear ribonuclear proteins proteins Cbf5p, Nhp2p and Nop10p. Nucleic Acid Res. 29, 598–603 (2001).
   PubMed Web of Science ®Google Scholar
• Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenital. Nature 402, 551–555 (1999).
   PubMed Web of Science ®Google Scholar
• Kelleher C, Kurth I, Lingner J. Human protection of telomeres 1(POT1) is a negative regulator of telomerase activity in vitro. Mol. Cell Biol. 25, 808–818 (2005).
   PubMed Web of Science ®Google Scholar
• Yang Q, Zheng YL, Harris CC. POT1 and TRF2 co-operate to maintain telomeric integrity. Mol. Cell Biol. 25, 1070–1080 (2005).
   PubMedGoogle Scholar
• Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J. Cell Physiol. 180(1), 10–18 (1999).
   PubMed Web of Science ®Google Scholar
• Wright WE, Piatyszek MA, Rainey WE. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 18, 98–103 (1996).
   Google Scholar
• Shay JW, Bacchetti. A survey of telomerase activity in human cancer. Eur. J. Cancer. 33, 787–791 (1997).
   PubMed Web of Science ®Google Scholar
• Hiyama KY, Hirai S, Kyoizumi M et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155, 3711–3715 (1995).
   PubMed Web of Science ®Google Scholar
• Greenberg RA, Allsopp RC, Chin L et al. Expression of mouse telomerase reverse transcriptase during development, differentiaition and proliferation. Oncogene 16, 1723–1730 (1998).
   PubMedGoogle Scholar
• Hande MP, Balajee AS, Natarajan AT. Induction of telomerase activity by UV irradiation in Chinese Hamster cells. Oncogene 15, 1747–1752 (1997).
   PubMedGoogle Scholar
• Aviv A. Telomeres and human aging: facts and fibs. Sci. Aging Knowledge Environ. 22(51), 43 (2004).
   Google Scholar
• Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787–791 (1997).
   PubMed Web of Science ®Google Scholar
• Counter CM, Avilion AA, Harley CB. Telomere shortening associated with chromosomal instability is arrested in immortal cells which express telomerase activity. EMBO J. 11, 1921–1929 (1992).
   PubMed Web of Science ®Google Scholar
• Cong Y, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of promoter. Hum. Mol. Genet. 8, 137–142 (1999).
   PubMed Web of Science ®Google Scholar
• Horikawa I, Cable PL, Afshari C. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 59, 826–830 (1999).
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Telomerase states and cell fates. Nature 408, 53–56 (2000).
   PubMed Web of Science ®Google Scholar
• Shay JW. Aging and cancer: are telomeres and telomerase the connection? Mol. Med. Today 1, 378–384 (1995).
   PubMedGoogle Scholar
• Bryan TM, Englezou A, Gupta J et al. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 14, 4240–4248 (1995).
   PubMed Web of Science ®Google Scholar
• La Torre D, de Divititis O, Conti A et al. Expression of telomeric reapeat binding factor 1 in astroglial brain tumors. Neurosurgery 56(4), 802–810 (2005).
   PubMedGoogle Scholar
• Wang J, Xie LY, Allan S et al. Myc activatea telomerase. Gene Dev. 12, 1769–1774 (1998).
   PubMed Web of Science ®Google Scholar
• Ohs S, Song YH, Yim J et al. Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene 19, 1485–1490 (2000).
   PubMedGoogle Scholar
• Greenberg RA, Allsopp RC, Chin L et al. Expression of mouse telomerase reverse transcriptase during development, differentiaition and proliferation. Oncogene 16, 1723–1730 (1998).
   PubMedGoogle Scholar
• Gunes CS, Lichtsteiner AP, Vasserot AP et al. Expression of hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res. 60, 2116–2121 (2000).
   PubMed Web of Science ®Google Scholar
• Fuxe J, Akusjarvi G, Goike HM et al. Adenovirus mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence and inhibits telomerase activity similarly to p16INK4A. Cell Growth Differ. 11, 373–384 (2000).
   PubMedGoogle Scholar
• Henderson YC, Breau RL, Liu J et al. Telomerase activity in head and neck tumors after induction of wild type p53, p21, p16 and E2F genes by means of recombinant Adenovirus. Head Neck 5, 347–354 (2000).
   Google Scholar
• Kanaya T, Kayo S, Hamada K et al. Adenoviral expression p53 repress telomerase activity through downregulation of human telomerase reverse transcriptase transcription. Clin. Cancer Res. 6, 1239–1247 (2000).
   PubMedGoogle Scholar
• Gollahon LS, Shay JW. Immortalization of human mammary epithelial cells transfected with mutant p53(273 his). Oncogene 15, 715–725 (1996).
   Google Scholar
• Kanaya T, Kyo S, Hamada K et al. Adenoviral expression of p53 represses telomerase activity through downregulation of human telomerase reverse transcriptase transcription. Clin. Cancer Res. 6, 1239–1247 (2000).
   PubMedGoogle Scholar
• Crowe DL, Nguyen DC, Tsang Kj et al. E2F1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acid Res. 29(13), 2789–2794 (2001).
   PubMed Web of Science ®Google Scholar
• Nguyen DC, Crowe DL. Intact functional domains of the retinoblastoma gene product (pRb) are required for downregulation of telomerase activity. Biochem. Biophys. Acta 1445, 207–215 (1999).
   PubMedGoogle Scholar
• Kirkpatrick KL, Ogunkolade W, Elkak AE et al. hTERT expression in human breast cancer and non-cancerous breast tissue: correlation with tumour stage and c-Myc expression. Breast Cancer Res. Treat. 77(3), 277–284 (2003).
   PubMedGoogle Scholar
• Mokbel K, Ghilchik M, Williams G et al. The association between telomerase activity and hormone receptor status and p53 expression in breast cancer. Int. J. Surg. Investig. 1(6), 509–516 (2000).
   PubMedGoogle Scholar
• Rhyu M. Telomeres, telomerase and immortality. J. Natl Cancer Inst. 87, 884–894 (1995).
   PubMed Web of Science ®Google Scholar
• O’Flatharta C, Leader M, Kay E et al. Telomerase activity detected in oral lichen planus by RNA in situ hybridisation: not a marker for malignant transformation. J. Clin. Pathol. 55, 602–607 (2002).
   PubMedGoogle Scholar
• Kammori M, Kanauchi H, Nakamura K et al. Demonstration of human telomerase reverse transcriptase in human colorectal carcinomas by in situ hybridisation. Int. J. Oncol. 20, 15–21 (2002).
   PubMedGoogle Scholar
• Chang LY, Lin SC, Wong YK et al. Telomerase activity and in situ telomerase RNA expression in oral carcinogenesis. J. Oral Pathol. Med. 28, 389–396 (1999).
   PubMedGoogle Scholar
• Jarobe EA, Liaw Ki, Thompson LC et al. Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma. Oncogene 21, 664–673 (2002).
   PubMedGoogle Scholar
• Melissourgos N, Kastrinakis NG, Davilas I et al. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumour marker. Urology 62, 362–367 (2003).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick KL, Newbold RF, Mokbel K. The mRNA expression of hTERT in human breast carcinomas correlates with VEGF expression. J. Carcinogen 3, 1 (2004).
   PubMedGoogle Scholar
• Snijders PJ, Breuer RH, Sutedja TG et al. Elevated hTERT mRNA levels: a potential determinant of bronchial squamous cell carcinomas (in situ). Int. J. Cancer 109, 412–417 (2004).
   PubMedGoogle Scholar
• Amioka T, Kitadai Y, Hiyam T et al. Expression of human telomerase reverse transciptase mRNA in oseophgeal cancer and precancerous lesions. 11(1), 51–55 (2004).
   Google Scholar
• Cabuy E, de Ridder L. Telomerase activity and expression of telomerase reverse transcription correlated with cellular proliferation in meningiomas and malignant brain tumors in vivo. Virchows Arch. 439(2), 176–184 (2001).
   PubMedGoogle Scholar
• Chou SJ, Chen CM, Harn HJ, Chen CJ, Liu YC. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma. J. Sur. Res. 99(1), 75–83 (2001).
   PubMedGoogle Scholar
• Elder EE, Xu D, Hoog A et al. Ki-67 and hTERT expression can aid in the distinction between malignant and benign pheochrocytoma and paraganglioma. Mod. Pathol. 16(3), 246–255 (2003).
   PubMedGoogle Scholar
• Holt SE, Norton JC, Wright WE et al. Comparison of the telomeric repeat amplification protocol (TRAP) to the new TRAP-eze telomerase detection kit. Methods Cell Sci. 18, 237–248 (1996).
   Google Scholar
• Krupp G, Kuhne K, Tamn S et al. Molecular basis of artifacts in the detection of telomerase activity and a modified primer for a more robust ‘TRAP’ assay. Nucleic Acid Res. 25, 919–921 (1997).
   PubMedGoogle Scholar
• Mabruk MJ. In situ hybridization: detecting viral nucleic acid in formalin-fixed, paraffin-embedded tissue samples. Expert Rev. Mol. Diagn. 4, 653–661 (2004).
   PubMed Web of Science ®Google Scholar
• Mutirangura A, Supiyaphun P, Trirekapan S et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res. 56, 3530–3533 (1996).
   PubMedGoogle Scholar
• Califano J, Ahrent S, Meininger G et al. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res. 56, 5720–5722 (1996).
   PubMed Web of Science ®Google Scholar
• Harada K, Yasoshima M, Ozaki S et al. PCR and in situ hybridization studies of telomerase subunits in human non-neoplastic livers. J. Pathol. 193, 210–217 (2001).
   PubMedGoogle Scholar
• Fujimoto R, Kamata N, Yokoyama K et al. Expression of telomerase components in oral keratinocytes and squamous cell carcinomas. Oral. Oncol. 37, 132–140 (2001).
   PubMedGoogle Scholar
• Zhang L, Zhang W. Telomerase hTR and hTRT gene expression in oral precancerous lesions and squamous cell carcinomas. Chin. J. Dent. Res. 2, 43–48 (1999).
   PubMedGoogle Scholar
• Yashima K, Litzky LA, Kaiser L et al. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung cancer. Cancer Res. 57, 2373–2737 (1997).
   PubMed Web of Science ®Google Scholar
• Yashima K, Ashfaq R, Nowak J et al. Telomerase activity and expression of its RNA component in cervical lesions. Cancer 82, 1319–1327 (1998).
   PubMed Web of Science ®Google Scholar
• Yao XX, Yin L, Sun ZC. The expression of hTERT mRNA and cellular immunity in gastric cancer and percancerosis. World J. Gastroenterol. 8, 586–590 (2002).
   PubMedGoogle Scholar
• Falchetti ML. Pallini R, D’Ambrosio E et al. In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme. Int. J. Cancer 88, 895–901 (2000).
   PubMed Web of Science ®Google Scholar
• Wang L, Soria JC, Kemp BL et al. hTERT expression is a prognostic factor of survival in patients with stage 1 non-small cell lung cancer. Clin. Cancer Res. 8, 2883–2889 (2002).
   PubMed Web of Science ®Google Scholar
• Fujita Y, Fujikane T, Fujiuchi S. The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patient with nonsmall cell lung carcinoma. Cancer 98, 1008–1013 (2003).
   PubMedGoogle Scholar
• Li C, Wu MY, Liang YR. Correlation between expression of human telomerase subunits and telomerase activity in esophageal squamous cell carcinoma. World J. Gastroenterol. 9, 2395–2399 (2003).
   PubMedGoogle Scholar
• Wang J, Zhong M, Wang Z. Expression of human telomerase reverse transcriptase and bcl-2 in ameloblastoma. Hua Xi Kou Qiang Yi Xue Za Zhi 21, 441–443 (2003).
   PubMedGoogle Scholar
• Nakanishi K, Hiroi S, Kawai T et al. Expression of telomerase catalytic subunit (hTERT) RNA does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Mod. Pathol. 14, 1073–1078 (2001).
   PubMedGoogle Scholar
• Bettendorf O, Heine B, Kneif S et al. Expression patterns of the RNA component (hTR) and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia and prostate cancer. Prostate 55, 99–104 (2003).
   PubMedGoogle Scholar
• Liu YC, Chen CJ, Wu HS et al. Telomerase and c-myc expression in hepatocellular carcinomas. Eur. J. Surg. Oncol. 30, 384–390 (2004).
   PubMedGoogle Scholar
• YI X, Shay JW, Wright WE. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acid Res. 29, 4818–4825 (2001).
   PubMed Web of Science ®Google Scholar
• Qu ZL, Zou SQ, Sun ZC et al. The expression and significance of human telomerase reverse transcriptase protein and gene in bile duct carcinomas and their adjacent tissues. Zhonghua Zhong Liu Za Zhi 26, 98–101 (2004).
   PubMedGoogle Scholar
• Ito Y, Yoshida H, Tooda C et al. Telomerase activity in thyroid neoplasms evaluted by the expression of human telomerase reverse transcriptase (hTERT). AntiCancer Res. 25, 509–514 (2005).
   PubMedGoogle Scholar
• Sabah M, Gummins R, Leader M. Expression of human telomerase reverse transcriptase in gastrointestinal stromal tumors occurs preferentially in malignant neoplasms. Hum. Pathol. 35, 1231–1235 (2004).
   PubMedGoogle Scholar
• Lantuejoul S, Soria JC, Moro-Sibilot D et al. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br. J. Cancer 90, 1222–1229 (2004).
   PubMed Web of Science ®Google Scholar
• Park HR, Min SK, Cho HD et al. Expression profiles of p63, p53, survivin, and hTERT in skin tumors. J. Cutan. Pathol. 31, 544–549 (2004).
   PubMed Web of Science ®Google Scholar
• Maes L, Lippens E, Kalala JP et al. The hTERT- protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas. Cell Prolif. 38, 3–12 (2005).
   PubMed Web of Science ®Google Scholar
• Krams M, Clavioz A, Heidom K et al. Regulation of telomerase activity by alternative splicing of human telomerase reverse transcriptase mRNA in subsets of neuroblastoma. Am. J. Pathol. 159, 1925–1932(2001).
   PubMed Web of Science ®Google Scholar
• Tchirkov A, Chaleteix C, Magnac C et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann. Oncol. 15, 1476–1480 (2004).
   PubMed Web of Science ®Google Scholar
• Takuma Y, Nouso K, Kobayashi Y et al. Telomerase reverse transcriptase gene amplification in hepatocellular carcinoma. J. Gastrenterol. Hepatol. 19, 1300–1304 (2004).
   PubMedGoogle Scholar
• Xi L, Zhu T, Wu P et al. Expression of human telomerase reverse transcriptase in cervix cancer and its significance. Zhonghua Fu Chan Ke Za Zhi 40, 407–410 (2005).
   PubMedGoogle Scholar
• Li YR, Wu JM, Wang L et al. Human telomerase reverse transcriptase expression and its clinical significance in laryngeal squamous cell carcinoma. Acta. Otolarygol. 125, 409–414 (2005).
   PubMed Web of Science ®Google Scholar
• Effros RB, Boucher N, Porter V et al. Decline in CD28+ T-cells in centenarians and in long-term T-cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp. Gerontol. 29, 601–609 (1994).
   PubMed Web of Science ®Google Scholar
• Lansdorp PM, Verwoerd NP, van de Rijke FM et al. Heterogeneity in telomere length of human chromosomes. Hum. Mol. Genet. 5, 685–691 (1996).
   PubMed Web of Science ®Google Scholar
• Hsu CP, Miaw J, Shai SE et al. Correlation between telomerase expression and terminal restriction fragment length ratio in non-small cell lung cancer-an adjusted measurment and its clinical significance. Eur. J. Cardiothorac. Surg. 26(2), 425–431 (2004).
   PubMedGoogle Scholar
• Kapoor V, Telford WG. Telomere length measurement by fluorescence in situ hybridization and flow cytometry. Methods Mol. Biol. 263, 385–398 (2004).
   PubMedGoogle Scholar
• Damle R, Batliwalla FM, Ghiotto F. Telomere length and telomerase activity delineate distinctive replicative features of the B-cell subgroups defined by immunoglobulin V gene mutation. Blood 103(2), 375–382 (2003).
   PubMedGoogle Scholar
• Ferlicot S, Youssef N, Feneux D et al. Measurment of telomere length on tissue sections using quantitative fluorescence in situ hybridization (Q-FISH). J. Pathol. 200(5), 661–666 (2003).
   PubMedGoogle Scholar
• Herrera E, Samper E, Martín-Caballero J et al. Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO J. 18, 2950–2960 (1999).
   PubMed Web of Science ®Google Scholar
• Samper E, Goytisolo F, Ménissier-de Murcia J et al. Normal telomere length and chromosomal end-capping in poly(ADP-ribose) polymerase deficient mice and primary cells despite increased chromosomal instability. J. Cell Biol. 154, 49–60 (2001).
   PubMedGoogle Scholar
• Meeker AK, Gage WR, Hicks JL et al. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am. J. Pathol. 160, 1259–1268 (2002).
   PubMed Web of Science ®Google Scholar
• Perner S, Bruderlein S, Hasel C et al. Quantifying telomere lengths of human individual chromosome arms by centromere-calibrated fluorescence in situ hybridization and digital imaging. Am. J. Pathol. 163(5), 1751–1756 (2003).
   PubMed Web of Science ®Google Scholar
• Bryan TM, Englezon A, Cupta J et al. Telomere elongation in immortal cells without detectable telomerase activity. EMBO J. 14, 4240–4248 (1995).
   PubMed Web of Science ®Google Scholar
• Dunham MA, Neuman AA, Fasching CL. Telomere maintenance by recombination in human cells. Nature Genet. 26, 447–450 (2000).
   PubMed Web of Science ®Google Scholar
• Byran TM, Englezon A, Dalla Z et al. Evidence of an alternative mechanism for maintaining telomere length in human tumors and human derived cell lines. Nature Med. 3, 1271–1274 (1997).
   PubMedGoogle Scholar
• O’Sullivan JN, Finley JC, Risques RA et al. Telomere length assessment in tissue section by quantitative FISH image analysis algorithms. Cytometry A 58(2), 120–131 (2004).
   PubMedGoogle Scholar
• Yeager TR, Neumann AA, Englezou A et al. Telomerase negative immortalized human cells contains a novel type of promyelocytic leukaemia (PML) body. Cancer Res. 59, 4175–4179 (1999).
   PubMed Web of Science ®Google Scholar
• Henson JD, Hannay JA, McCarthy SW et al. A robust assay for alternative lengthening of telomeres in tumors shows significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin. Cancer Res. 11(1), 217–225 (2005).
   PubMed Web of Science ®Google Scholar